Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Significant Decrease in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 33,700 shares, a decrease of 18.0% from the September 30th total of 41,100 shares. Based on an average daily volume of 521,500 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.7% of the shares of the stock are short sold.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH traded down $0.16 during trading hours on Wednesday, reaching $1.64. 627,698 shares of the stock traded hands, compared to its average volume of 479,053. Shuttle Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $4.95. The company has a market capitalization of $4.84 million, a P/E ratio of -0.52 and a beta of -0.94. The company’s 50-day simple moving average is $1.53.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.96) EPS for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .